Eliaz Therapeutics has started a Regulation Crowdfunding round to fund GLP safety studies and first-in-human trials of XGal-3, an apheresis device targeting Galectin-3 to treat sepsis. The device has FDA Breakthrough Device Designation and aims to address sepsis by removing a key inflammatory protein, potentially improving survival. With $8M raised and strong preclinical data, the company plans to expand clinical development and explore broader applications for Galectin-3-related diseases.
HTX, a crypto exchange owned by Justin Sun, transferred $1.3 billion of its reserve funds to an undisclosed third-party custodian following UK sanctions accusing it of aiding Russian entities. This move likely aims to protect legitimate users from ha...
HF Foods Group Inc. announced its Board of Directors has approved a limited duration stockholder rights plan to protect against undisclosed stock accumulation and coordinated efforts to gain control of the company. The plan grants one right per share...
OpenAI has acquired cloud-based developer Ona to enhance its Codex AI platform with secure, customer-controlled cloud infrastructure. This acquisition enables Codex to perform long-running AI tasks across devices and sessions, even when offline, sign...
Cloud3 Ventures Inc. has increased the size of its non-brokered private placement to issue up to 5 million shares at $0.06 each, aiming to raise $300,000. The funds will be used for general working capital and corporate purposes. The offering is subj...
L.B. Foster Company announced that its executives Bill Thalman and Sean Reilly will present virtually at the Sidoti Small Cap Virtual Conference on June 18, 2026. The presentation will start at 10:45 AM EDT, with materials available on the company's ...
